The most clinically validated breast AI presented in 4 major peer-reviewed studies in the last 6 months, better workflow to increase detection capacity for radiologists and women.

VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ScreenPoint Medical is showcasing the global momentum of Transpara, the world's leading breast artificial intelligence (AI) software, here at the European Society of Imaging Annual Scientific Meeting Mammary (EUSOBI), from September 28 to 30, 2023 (stand M02).

The clinical and operational value of Transpara in improving the mammography process has been documented in several top peer-reviewed publications in recent months, including Lancet Oncology, Journal of Clinical Oncology, and European Radiology.

Headlining the publications are preliminary results from the first randomized controlled trial in Breast AI: the Mammography Study with AI (MASAI) published this summer in Lancet Oncology. This study investigated the use of AI in breast cancer detection to classify 90% of cases in a single reading and the results were surprising: Transpara-assisted workflow boosted cancer detection (20%) and safely reduced read workload by 44% with no change in recovery or arbitrage rate. Transpara is already being used in regions of three European countries to safely replace the second reader in low-risk screening mammograms to offer more timely care to women; Ongoing research continues to affirm the value of Transpara in these settings.

MASAI focused on improving workflow to address the global radiology capacity shortage. As technological advances offer more ways for radiology to support diagnosis and treatment selection, the work of radiologists is gaining importance. The research using Transpara to improve workflow is not limited to reading volume. Better breast care for women includes effective risk stratification; Two papers studying Transpara published this year demonstrated that safe and effective risk assessment may not require a manual, labor-intensive data collection process.

Earlier this year, researchers from the Mayo Clinic (Rochester, MN) and the University of California, San Francisco confirmed that combining artificial intelligence (AI) imaging and volumetric breast density algorithms can help predict the long-term risk of breast cancer, particularly invasive disease. The study, “Impact of Artificial Intelligence System and Volumetric Density on Predicting the Risk of Advanced, Screen-Detected and Interval Breast Cancer,” was published in the Journal of Clinical Oncology. The results showed that the Transpara score improves long-term risk prediction when combined with clinical risk factors, including breast density, for overall invasive cancers, screen-detected, advanced, and non-advanced cancers.

Additionally, the utility of Transpara in risk assessment based on effective and efficient screening programs was evaluated and published as “Breast Cancer Risk Assessment by Combining AI for Lesion Detection and Mammographic Texture.” Lauritzen, et al were able to demonstrate that the combination of Transpara-based detection, volumetric density, and quantitative texture analysis combined to deliver improved risk prediction compared to traditional, labor- and data-intensive risk models. Additionally, the additional imaging offered to women at higher risk from Transpara DOUBLED early cancer detection (finding interval cancer before subsequent visits) relative to traditional models.

One of the biggest risk factors for women continues to be breast density. This fact has fostered a global push to better characterize and communicate density. Transpara mitigates some of the detection risk associated with density. In summary: In the first quarter of the year, the study, "Artificial Intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1,254 breast cancer cases," published in European Radiology, researchers demonstrated the value of Transpara to support earlier detection in women with dense breasts, increasing sensitivity from 63% to 81%. The high proportion of cancers with a Transpara score of 10 indicates the promising performance of Transpara, especially for women with dense breasts. Previous mammogram results with a Transpara score of 10 illustrate the potential for earlier detection of breast cancers using AI in screen reading.

"As we reach nearly 5 million mammograms analyzed, we are very proud that Transpara continues to demonstrate value to breast healthcare providers and women when rigorously evaluated. These studies have validated Transpara's performance in helping radiologists detect cancer earlier and safely reduce workload," said Mark Koeniguer, CEO of ScreenPoint Medical.

About ScreenPoint Medical

ScreenPoint Medical translates cutting-edge machine learning research into technology accessible to radiologists to improve screening workflow, decision confidence, and breast cancer risk assessment. Transpara is trusted by radiologists around the world because it has been developed by experts in machine learning and image analysis and updated with feedback from users of world-renowned breast imagers.

View all evidence at: https://screenpoint-medical.com/published-evidence/peer-reviewed-publications

Photo - https://mma.prnewswire.com/media/2222821...Logo - https://mma.prnewswire.com/media/1582198...

View original content: https://www.prnewswire.com/news-releases/screenpoint-medical-muestra-el-impulso-global-de-la-ia-mamaria-transparar-en-eusobi-301940656.html